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Abstract
Background: The E-selectin p. S128R (g. A561C) polymorphism has been associated with the
presence of angiographic coronary artery disease (CAD) in some populations, but no data is
currently available on its association with CAD in Arabs.
Methods: In the present study, we determined the potential relevance of the E-selectin S128R
polymorphism for severe CAD and its associated risk factors among Arabs. We genotyped Saudi
Arabs for this polymorphism by PCR, followed by restriction enzyme digestion.
Results: The polymorphism was determined in 556 angiographically confirmed severe CAD
patients and 237 control subjects with no CAD as established angiographically (CON). Frequencies
of the S/S, S/R and R/R genotypes were found as 81.1%, 16.6% and 2.3% in CAD patients and 87.8%,
11.8%, and 0.4% in CON subjects, respectively. The frequency of the mutant 128R allele was higher
among CAD patients compared to CON group (11% vs. 6%; odds ratio = 1.76; 95% CI 1.14 – 2.72;
p = .007), thus indicating a significant association of the 128R allele with CAD among our
population. However, the stepwise logistic regression for the 128R allele and different CAD risk
factors showed no significant association.
Conclusion: Among the Saudi population, The E-selectin p. S128R (g. A561C) polymorphism was
associated with angiographic CAD in Univariate analysis, but lost its association in multivariate
analysis.
Background
E-selectin (endothelial leukocyte adhesion molecule;
ELAM1) is an 11-kD cell surface glycoprotein expressed
on endothelial cells after activation by cytokines, and
mediates adhesion of circulating monocytes and lym-
phocytes to endothelial cells. This adherence to activated
arterial endothelium is one of the earliest detectable
events in the pathogenesis of atherosclerosis [1]. Double-
knockout mouse experiments suggested that E-selectin
plays an essential role in both early and advanced stages
of atherosclerotic lesion development and that mutations
in cellular adhesion molecules like E-selectin may act as
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Additionally, the involvement of E-selectin in cardiovas-
cular diseases is suggested by the fact that it is expressed
only in activated endothelial cells. Amino acid change
from serine (S) to arginine (R) at codon 128 (S128R),
which corresponds to A > C nucleotide change at position
561 (A561C), in the epidermal growth factor-like domain
of the E-selectin gene has been implicated in the patho-
genesis of CAD in several ethnic groups, including Ger-
mans, Japanese, Americans, Chinese and Africans [4-10].
The 128R mutant allele was significantly higher in the
CAD patients than in controls (12.6% versus 6.7%, 17.4%
versus 7.1%, and 19.5% versus 10.6%) in Japanese, [4]
German [11] and white American [6] populations, respec-
tively. However, no previous studies are available on pos-
sible association of this polymorphism with CAD among
Arabs. Furthermore, apart from a study, which did not
find a link between this mutation and CAD in Austrian
patients with diabetes mellitus [12], there is hardly any
data in the literature pertaining to the possible association
of this mutation for the different CAD risk factors. There-
fore, the aim of this investigation was to evaluate the
potential relevance of E-selectin 128R polymorphism for
angiographic CAD and its risk factors in Arabs, using the
Saudi population as a study model.
Methods
Study population
Two groups of Saudi individuals were recruited for the
present study. The patient group comprised 556 candi-
dates (396 males and 160 females; mean age 50 ± 16 yr)
of Saudi Arabian descent with angiographically docu-
mented severe CAD. The inclusion criterion for CAD was
the presence of angiographically determined narrowing of
the coronary vessels by at least 70%, which we define as
having severe disease. Exclusion criteria for CAD were
major cardiac rhythm disturbances, incapacitating or life-
threatening illness, major psychiatric illness or substance
abuse, history of cerebral vascular disease, neurological
disorder, and administration of psychotropic medication.
A second group of 237 individuals (105 males and 132
females, mean age 50 ± 17 yr) undergoing surgery for
heart valvular diseases and those who reported with chest
pain, but were established to have no significant coronary
stenosis by angiography, were recruited as angiographed
controls (CON). Exclusion criteria for this group included
among others diseases such as cancer, autoimmune dis-
ease, or any other disorders likely to interact with varia-
bles under investigation. This study was performed in
accordance with the regulations laid down by the Hospi-
tal Ethics Committee and all participants signed an
informed consent.
DNA preparation
Five ml of peripheral blood were collected in EDTA tubes
from all participating individuals after obtaining their
written consent. DNA was extracted using the PURGENE
kit from Gentra Systems (Minneapolis, MN, USA), and
stored at -20°C in aliquots until required.
Determination of CAD risk factors
Serum cholesterol and triglyceride levels were measured
as routine in the main Hospital Pathology Laboratory.
Triglyceride levels >1.8 mmol/L and total cholesterol lev-
els > 5.2 mmol/L were considered elevated. Diabetic
patients either had a known history of diabetes mellitus or
were diagnosed as such according to the American Diabe-
tes Association criteria [13]. Diagnosis of myocardial inf-
arction was based on the consensus specified by the
European Society of Cardiology and the American College
of Cardiology [14]. Body mass index (BMI) was deter-
mined for all participants, and individuals with BMI ≥ 30
were considered obese in accordance with the Center for
Disease Control and Prevention (Atlanta, GA, USA).
Information about all other risk factors was procured
either through patient interviews or by referring to their
medical records.
Detection of the S128R (A561C) polymorphism
This was carried out by polymerase chain reaction (PCR)
amplification followed by PstI restriction enzyme diges-
tion. For DNA amplification, we used the forward primer
5'- AGT AAT AGT CCT CCT CAT CAT G -3' and reverse
primer 5'- ACC ATC TCA AGT GAA GAA AGA G-3',
designed to amplify a 186 bp fragment of the E-selectin
gene [6,11]. Each 25 µl PCR reaction contained 2.5 µl of
10X reaction buffer with MgCl2 (Amersham Pharmacia
Biotech, Piscataway, NJ, USA), 10 ρmol of each primer,
100 ρmol/µl each of deoxynucleoside triphophates
(deoxyadenosine triphosphate, deoxyguanosine triphos-
phate, deoxycytidine triphosphate and deoxythymidine
triphosphate) (Perkin-Elmer Corporation, Foster City,
CA, USA) in Tris HCl buffer, 1 unit Taq DNA polymerase
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) and
50 ng genomic DNA template. The mixture was denatured
at 95°C for 5 min and the PCR reaction was carried out for
35 cycles, in a GeneAmp 9600 PCR system (Perkin-Elmer
Corporation, Foster City, CA, USA), under the following
conditions: denaturation at 95°C for 1 min, annealing at
54°C for 45 sec, extension at 72°C for 1 min and final
extension cycle of 72°C for 7 min. The PCR products were
electrophoresed on a 1% agarose gel and detected with 0.5
µg/ml ethidium bromide to confirm the correct amplicon
size. The products were digested using the PstI restriction
enzyme (Stratagene, LaJolla, Calif, USA) and the resultant
fragments resolved on a 4% MetaPhor agarose gel (FMC
Bio-products, Rockland, Maine, USA) in TE buffer con-
taining 0.5 µg/ml ethidium bromide. The sizes of thePage 2 of 5
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der (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
As a quality control, we confirmed by direct sequencing
the genotype status of 384 random samples representing
the three different genotypes.
Statistical analysis
Genotype frequencies in various groups were compared
by Chi-Square test. Multivariable logistic regression was
used to study the effect of the E-selectin 561 C allele (128R
allele) on CAD status, incorporating other variables (cor-
onary risk factors) into the model. Additionally, we tried
multiple logistic regression models involving the inclu-
sion of interaction of the genotype × different CAD risk
factors. All analyses were performed using SPSS v.10
(SPSS Inc., Chicago, USA) statistical analysis software. A
two-tailed p value < .05 was considered statistically signif-
icant. We did power analysis employing the nQuery
Adviser version.4 using two scenarios described in the
results section and we concluded from this analysis that
the study was adequately powered.
Results
In the angiographically confirmed CAD patients (n =
556), 451 (81.1%) were homozygous S/S genotype, 92
(16.6%) were heterozygous S/R and 13 (2.3%) were
homozygous for the R/R (Table 1). Among the CON
group (n = 237), 208 (87.8%) were S/S, 28 (11.8%) were
S/R and 1 (0.4%) was R/R genotype. When we compared
the prevalence of the different genotypes between the
CAD and CON groups, the odds ratio for the S/R genotype
was 1.52 (95% CI: 0.94 – 2.45; p = .07) and that for the R/
R genotype was 6.0 (95% CI: 0.82 – 123.6; p = .05).
We found that the mutant 128R allele accounted for 11%
in the CAD group, which was significantly higher than
that in the CON group (6%). The odds ratio for the risk of
CAD associated with the 128R allele was 1.76 (95% CI
1.14 – 2.72; p = .007), thus indicating a significant associ-
ation of this allele with CAD in our population.
The variables showing an association (p =< .05) from
Table 1, were then put into a stepwise logistic regression,
in order to study the possible combined effect of the
mutant 128R allele with other risk factors on angiographic
CAD. The variables retained in the model were hyperten-
sion (p = .03), diabetes mellitus (DM) (p =< .001), hyper-
cholesterolemia (p =< .001), hypertriglyceridemia (p =
.008), MI (p =< .001) and gender (p =< .001) (Table 2).
Table 1: Crude odds ratio for all CAD risk factors among CAD and CON groups
Risk factor Status Total CAD CON Odds ratio 95% C.I P value
Genotype S/S 659 451 208 - - -
S/R 120 92 28 1.52 0.94 – 2.45 .07
R/R 14 13 1 6.0 0.82 – 123.6 .05
Alleles S 1438 994 444 - - -
R 148 118 30 1.76 1.14 – 2.72 .007
Age < 40 207 139 68 - - -
≥ 40 586 417 169 1.20 0.86 – 1.69 .29
Hypercholester
olemia
No 252 73 179 - - -
Yes 541 483 58 20.4 13.8 – 30.0 <.001
DM No 382 194 188 - - -
Yes 411 362 49 7.16 4.9 – 10.2 <.001
FH No 544 376 168 - - -
Yes 249 180 69 1.1 0.84 – 1.62 .40
Gender F 292 160 132 - - -
M 501 396 105 3.11 2.3 – 4.3 <.001
Hypertension No 120 49 71 - - -
Yes 673 507 166 4.42 2.95 – 6.62 <.001
MI No 599 368 231 - - -
Yes 194 188 6 19.7 8.5 – 45.1 <.001
Obesity No 73 45 28 - - -
Yes 720 511 209 0.65 0.39 – 1.08 .07
Smoking No 667 462 205 - - -
Yes 126 94 32 1.30 0.84 – 2.01 .25
Hypertriglyceri
demia
No 247 90 157 - - -
Yes 546 466 80 10.2 7.1 – 14.4 <.001
DM, diabetes Mellitus; FH, family history of CAD; MI, myocardial infarction on admission; hypertriglyceridemia (>1.8 mmol/L); 
hypercholesterolemia (> 5.2 mmol/L) and obesity (Body Mass Index ≥ 30).Page 3 of 5
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employing nQuery Adviser version 4 using two scenarios
as follow: First, In our study, when we compared the risk
of CAD among (S/R and R/R) to S/S, we got an odds ratio
of 1.67 (p = .023). When α =.05, using 2 sided test, pro-
portion of S/R and R/R among CAD is .189 and among
controls is .122. Number of controls = 237, number of
cases = 556 (we used the average, which is 397). Using this
information we have calculated the power in nQuery as
74%. Second, In our study, when we analyzed the risk of
CAD among (R alleles) compared to S alleles, we got an
odds ratio of 1.7 (p = .007). When α = .05, using 2 sided
test, proportion of C alleles among CAD is .106 and
among controls is .063. Number of controls = 474,
number of cases = 1112 (we used the average, which is
793). Using this information, we have calculated the
power in nQuery as 86%. From this power calculation, we
concluded that our study is adequately powered.
Discussion
In the past 3 decades, the incidence of CAD is on the rise
in Saudi Arabia. According to the biggest study conducted
so far, the overall prevalence of this disease in Saudi Ara-
bia is 5.5% [15]. The rise in the incidence of CAD has been
attributed to the major changes in the life-style of the
Saudi population. High-fat diets, obesity, diabetes, and
smoking, all of which are considered CAD risk factors,
have become more prevalent, and people are leading a
more sedentary lifestyle. Two independent studies
reported predicted an incremental scale for the develop-
ment of CAD in the Saudi population because of sharp
increases in CAD risk factors such as obesity, hypercholes-
terolemia, diabetes, hypertriglyceridemia, and high blood
pressure [16,17]. Early detection of individuals genetically
susceptible to CAD can lead to early intervention, and
knowledge of genetic susceptibility to CAD has value in
providing risk information and guiding decision-making.
To our knowledge, this study is the first to evaluate the
prevalence of E-selectin polymorphism (S128R) and its
potential relevance for angiographic CAD and its associ-
ated risk factors in the Arab population. The first step was
to determine the prevalence of different E-selectin geno-
types among our general population of Saudi Arabs. We
found that the S/S is the most abundant and R/R the least
common genotype among Arabs. The prevalence of the
128R allele was 6% in our controls, which is almost simi-
lar to the rate observed in the Germans (7.1%) and Japa-
nese (6.7%) and slightly higher that in Africans (3.7%) [9]
and Chinese (0%) [10]. When we compared the genotype
frequencies in CAD versus CON group, the odds ratio was
significant, indicating an association between these geno-
types and CAD.
However, possibly because of the relatively small number
of individuals with the S/R and R/R genotype, this analysis
did not attain significance see Table 1. On the other hand,
a significant odds ratio and p value was obtained when we
compared the frequency of the 128R mutant allele in CAD
and CON groups, pointing to an association of this allele
with CAD among our Saudi Arab population. These
results are comparable to the findings in the Japanese [4],
German [11] white American [6] and Chinese [10] popu-
lations, but in contrast to a previous study in CAD
patients with type 2 DM [12]. Although the frequencies of
several classical risk factors for CAD, including elevated
cholesterol and triglycerides levels, DM, age, hyperten-
sion, gender and MI were higher in the CAD patients com-
pared to controls, when we entered these risk factors with
the mutant 128R allele into a multiple variable logistic
regression, the association was no longer significant.
Conclusion
In summary, the mutant 128R allele of the E-selectin gene
is associated with angiographic severe CAD in Saudi
Arabs. This association is lost after adjustment for tradi-
tional CAD risk factors.
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Table 2: Results of multiple logistic regression analysis: final significant variables in equation
Risk Factor (variables) Odds ratio [95% C.I] p value
Hypertension 1.53 1.03 – 2.26 .03
DM 3.95 2.85 – 5.48 <.001
Hypercholesterolemia 7.96 5.30 – 11.9 <.001
Hypertriglyceridemia 1.72 1.15 – 2.58 .008
MI 14.1 7.45 – 26.7 <.001
Gender 2.36 1.73 – 3.23 <.001Page 4 of 5
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